Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.
Preparation Methods and Antioxidant activity of Quinic acid
Quinic acid is an endogenous cyclitol carboxylic acid that is widely distributed in plants, and Quinic acid is a central intermediate of the shikimate pathway and the core skeleton of chlorogenic acid
Oct 25,2026 APIPreparation Methods and Coupling Reaction of 5-Bromo-m-xylene
5-Bromo-m-xylene can be prepared from 2,4-dimethylaniline through a diazotization–bromination reaction, and 5-Bromo-m-xylene is mainly used as a basic chemical reagent for organic synthesis.
Oct 25,2026 APIPreparation Methods and Biological Activity of ALPHA-CARYOPHYLLENE
ALPHA-CARYOPHYLLENE has been shown in in vitro experiments to exhibit cytotoxicity against adenocarcinomas such as colorectal, pulmonary, breast, prostatic, lung, and ovarian cancers.
Oct 25,2026 APIBioeffects of 2-Chloroacetophenone
2-Chloroacetophenone is an intermediate with reactive chlorine atoms and forms bulky N7-alkylguanine DNA adducts but shows nonmutagenic properties.
Oct 24,2026 APIPrednisone 21-acetate: Pharmacology and Application
Prednisone 21-acetate is a lipophilic synthetic glucocorticoid prodrug which is widely used for inflammatory, allergic and autoimmune disorders.
Oct 24,2026 APISodium Phosphate Monobasic Monohydrate Applications
Sodium phosphate monobasic monohydrate is a phosphate with good buffering capacity, widely used in food industry and biochemical PBS preparation.
Oct 23,2026 APIResearch Progress on Biosynthesis and High-Yield Strategies of FR901379
The compound FR901379, a sulfated echinocandin, is an important intermediate for the synthesis of the antifungal drug micafungin.
Oct 23,2026 APIHexarelin: Benefits, Side Effects, and Dosage
Hexarelin (HEXA) a synthetic hexapeptide with sustained andreproducible GH-releasing effect, can bind to and activate the growth hormone secretagogue receptor (GHSR) in the brain similar to its natura
Oct 22,2026 APIToxicity of 3-(4-METHYLBENZYLIDENE)CAMPHOR
3-(4-Methylbenzylidene)camphor acts as an endocrine disruptor that triggers reproductive and developmental toxicity in fish and inhibits aquatic primary production.
Oct 22,2026 APIWhat is Temozolomide used for?
Temozolomide is an orally available monofunctional DNA alkylating agent of the imidazotetrazine class.It was granted FDA approval in the treatment of recurrent an aplastic astrocytoma in 1999.
Oct 22,2026 API












